Advertisement

Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto—GBG 84): A randomised phase III trial

Published:December 04, 2018DOI:https://doi.org/10.1016/j.ejca.2018.10.015

      Highlights

      • In high-risk early breast cancer (BC), pathological complete response (pCR) rates of intense dose-dense epirubicin, paclitaxel, and cyclophosphamide (iddEPC) and weekly paclitaxel plus non-pegylated liposomal doxorubicin with additional carboplatin in triple-negative breast cancer PM(Cb) were similar.
      • Weekly PM(Cb) led to more dose reductions, treatment delays and overall toxicity.
      • In patients with lymphocyte-predominant BC, pCR rate was significantly higher with iddEPC.

      Abstract

      Background

      GeparOcto compared efficacy and safety of two chemotherapy regimens in high-risk early breast cancer (BC): sequential treatment with intense dose-dense epirubicin, paclitaxel, and cyclophosphamide (iddEPC) and weekly treatment with paclitaxel plus non-pegylated liposomal doxorubicin (M, Myocet®) with additional carboplatin (PM(Cb)) in triple-negative BC (TNBC).

      Patients and methods

      Patients with cT1c-cT4a-d and centrally assessed human epidermal growth factor receptor (HER)2-positive BC or TNBC were eligible, irrespective of nodal status, luminal B-like tumours only if pN+.
      Patients were randomised (stratified by BC subtype, Ki67, lymphocyte-predominant BC) to receive 18 weeks of E (150 mg/m2) followed by P (225 mg/m2) followed by C (2000 mg/m2), each q2w for 3 cycles or weekly P (80 mg/m2) plus M (20 mg/m2) plus, in TNBC, Cb (area under curve (AUC) 1.5). HER2-positive BC patients additionally received trastuzumab (6 [loading dose 8]mg/kg q3w) and pertuzumab (420 [840]mg q3w) with all P and C cycles. Primary end-point was pathological complete response (pCR, ypT0/is ypN0), secondary end-points included other pCR definitions, pCR in stratified subpopulations, tolerability and compliance. This trial is registered with ClinicalTrials.gov number NCT02125344.

      Results

      945/961 randomised patients started treatment. The median age was 48 years; 7.6% had cT3-4, 46% cN+, 66% G3, 40% HER2-positive, 43% TNBC. pCR rate with iddEPC was 48.3%, with PM(Cb) 48.0%, respectively (PM(Cb) versus iddEPC odds ratio 0.99; 95% confidence interval 0.77–1.28, P = 0.979) with no significant differences observed in TNBC, HER2-positive, luminal B-like subtypes. 16.4% with iddEPC and 34.1% with PM(Cb) discontinued treatment (P < 0.001), mainly due to adverse events; two patients on PM(Cb) died.

      Conclusions

      In high-risk early BC there is no difference in pCR rates following neoadjuvant treatment with iddEPC or weekly PM(Cb), respectively. iddEPC is one of the effective dose-dense regimens feasible in daily practice.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kaufmann M.
        • Hortobagyi G.N.
        • Goldhirsch A.
        • Scholl S.
        • Makris A.
        • Valagussa P.
        • et al.
        Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.
        J Clin Oncol. 2006; 24: 1940-1949
        • Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
        Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials.
        Lancet Oncol. 2018; 19: 27-39
        • Chen A.M.
        • Meric-Bernstam F.
        • Hunt K.K.
        • Thames H.D.
        • Outlaw E.D.
        • Strom E.A.
        • et al.
        Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience.
        J Clin Oncol. 2004; 22: 2303-2312
        • Cortazar P.
        • Zhang L.
        • Untch M.
        • Mehta K.
        • Costantino J.P.
        • Wolmark N.
        • et al.
        Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
        Lancet. 2014; 384: 164-172
        • von Minckwitz G.
        • Untch M.
        • Blohmer J.U.
        • Costa S.D.
        • Eidtmann H.
        • Fasching P.A.
        • et al.
        Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
        J Clin Oncol. 2012; 30: 1796-1804
        • Citron M.L.
        • Berry D.A.
        • Cirrincione C.
        • Hudis C.
        • Winer E.P.
        • Gradishar W.J.
        • et al.
        Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
        J Clin Oncol. 2003; 21: 1431-1439
        • Moebus V.
        • Jackisch C.
        • Lueck H.J.
        • du Bois A.
        • Thomssen C.
        • Kurbacher C.
        • et al.
        Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.
        J Clin Oncol. 2010; 28: 2874-2880
        • Möbus V.
        • Jackisch C.
        • Lueck H.J.
        • du Bois A.
        • Thomssen C.
        • Kuhn W.
        • et al.
        Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial.
        Ann Oncol. 2018; 29: 178-185
        • Sparano J.A.
        • Zhao F.
        • Martino S.
        • Ligibel J.A.
        • Perez E.A.
        • Saphner T.
        • et al.
        Long-term follow-up of the E1199 phase III trial evaluating the role of taxane and schedule in operable breast cancer.
        J Clin Oncol. 2015; 33: 2353-2360
        • Gray R.
        • Bradley R.
        • Braybrooke J.
        • Davies C.
        • Pan H.
        • Peto R.
        • et al.
        Increasing the dose density of adjuvant chemotherapy by shortening intervals between courses or by sequential drug administration significantly reduces both disease recurrence and breast cancer mortality: an EBCTCG meta-analysis of 21,000 women in 16 randomised trials.
        Cancer Res. 2018; 78: GS1-01
        • Romond E.H.
        • Perez E.A.
        • Bryant J.
        • Suman V.J.
        • Geyer Jr., C.E.
        • Davidson N.E.
        • et al.
        Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
        N Engl J Med. 2005; 353: 1673-1684
        • Untch M.
        • Fasching P.A.
        • Konecny G.E.
        • Hasmüller S.
        • Lebeau A.
        • Kreienberg R.
        • et al.
        Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
        J Clin Oncol. 2011; 29: 3351-3357
        • Gianni L.
        • Pienkowski T.
        • Im Y.H.
        • Roman L.
        • Tseng L.M.
        • Liu M.C.
        • et al.
        Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
        Lancet Oncol. 2012; 13: 25-32
        • Schneeweiss A.
        • Chia S.
        • Hickish T.
        • Harvey V.
        • Eniu A.
        • Hegg R.
        • et al.
        Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).
        Ann Oncol. 2013; 24: 2278-2284
        • von Minckwitz G.
        • Procter M.
        • de Azambuja E.
        • Zardavas D.
        • Benyunes M.
        • Viale G.
        • et al.
        Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer.
        N Engl J Med. 2017; 377: 122-131
        • von Minckwitz G.
        • Schneeweiss A.
        • Loibl S.
        • Salat C.
        • Denkert C.
        • Rezai M.
        • et al.
        Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
        Lancet Oncol. 2014; 15: 747-756
        • Sikov W.M.
        • Berry D.A.
        • Perou C.M.
        • Singh B.
        • Cirrincione C.T.
        • Tolaney S.M.
        • et al.
        Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
        J Clin Oncol. 2015; 33: 13-21
        • Geyer C.E.
        • O'Shaughnessy J.
        • Untch M.
        • Sikov W.
        • Rugo H.S.
        • McKee M.D.
        • et al.
        Phase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple-negative breast cancer (TNBC).
        J Clin Oncol. 2017; 35 (suppl. abstr.520)
        • von Minckwitz G.
        • Loibl S.
        • Schneeweiss A.
        • Salat C.T.
        • Rezai M.
        • Zahm D.-M.
        • et al.
        Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive breast cancer (GeparSixto).
        Cancer Res. 2015; 76: S2-S04
        • Hahnen E.
        • Lederer B.
        • Hauke J.
        • Loibl S.
        • Kröber S.
        • Schneeweiss A.
        • et al.
        Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial.
        JAMA Oncol. 2017; 3: 1378-1385
        • Pearson S.
        • Clopper C.
        The use of confidence or fiducial limits illustrated in the case of the binomial.
        Biometrika. 1934; 26: 404-413
      1. National Comprehensive Cancer Network Guidelines. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf [accessed on 10.07.2018].

        • Sparano J.A.
        • Wang M.
        • Martino S.
        • Jones V.
        • Perez E.A.
        • Saphner T.
        • et al.
        Weekly paclitaxel in the adjuvant treatment of breast cancer.
        N Engl J Med. 2008; 358: 1663-1671
        • Del Mastro L.
        • De Placido S.
        • Bruzzi P.
        • De Laurentiis M.
        • Boni C.
        • Cavazzini G.
        • et al.
        Flourouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 x 2 factorial, randomized phase 3 trial.
        Lancet. 2015; 385: 1863-1872
      2. Arbeitsgemeinschaft Gynäkologische Onkologie. Guidelines of the AGO Breast Committee, https://www.ago-online.de/en/guidelines-mamma/march-2018/[accessed on 09.07.2018].

        • e.V. Deutsche Krebsgesellschaft
        ([accessed 10 July 2018])
        • Möbus V.
        • von Minckwitz G.
        • Jackisch C.
        • Lück H.J.
        • Schneeweiss A.
        • Tesch H.
        • et al.
        German adjuvant intergroup node-positive study (gain): a phase III trial comparing two dose-dense regimens (iddEPC vs. ddEC-PwX) in high-risk early breast cancer patients.
        Ann Oncol. 2017; 28: 1803-1810
        • Swain S.
        • Tang G.
        • Geyer Jr., C.E.
        • Rastogi P.
        • Atkins J.N.
        • Donnellan P.P.
        • et al.
        Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.
        J Clin Oncol. 2013; 31: 3197-3204
        • Untch M.
        • Jackisch C.
        • Schneeweiss A.
        • Conrad B.
        • Aktas B.
        • Denkert C.
        • et al.
        Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial.
        Lancet Oncol. 2016; 17: 345-356
        • Untch M.
        • Möbus V.
        • Kuhn W.
        • Muck B.R.
        • Thomssen C.
        • Bauerfeind I.
        • et al.
        Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer.
        J Clin Oncol. 2009; 27: 2938-2945
        • Untch M.
        • Fasching P.A.
        • Konecny G.E.
        • von Koch F.
        • Conrad U.
        • Fett W.
        • et al.
        PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel +/- darbepoetin alfa in primary breast cancer – results at the time of surgery.
        Ann Oncol. 2011; 22: 1988-1998
        • Denkert C.
        • von Minckwitz G.
        • Darb-Esfahani S.
        • Lederer B.
        • Ingold-Heppner B.
        • Weber K.E.
        • et al.
        Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
        Lancet Oncol. 2018; 19: 40-50
        • Mark M.
        • Thürlimann B.
        Fatal pneumonitis after treatment with pegylated liposomal doxorubicin in a patient with metastatic breast cancer in complete remission.
        Med Oncol. 2012; 29: 1477-1478
        • Inaba K.
        • Arimoto T.
        • Hoya M.
        • Kawana K.
        • Nakagawa S.
        • Kozuma S.
        • et al.
        Interstitial pneumonitis induced by pegylated liposomal doxorubicin in a patient with recurrent ovarian cancer.
        Med Oncol. 2012; 29: 1255-1257
        • Levine M.
        • Pritchard K.
        • Bramwell V.
        • Shepherd L.E.
        • Tu D.
        • Paul N.
        • et al.
        Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5.
        J Clin Oncol. 2005; 23: 5166-5170